The Manufacturers Life Insurance Company bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 41,501 shares of the biotechnology company's stock, valued at approximately $22,486,000. The Manufacturers Life Insurance Company owned about 0.10% of United Therapeutics as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Torren Management LLC purchased a new position in United Therapeutics in the 4th quarter worth $26,000. Activest Wealth Management lifted its holdings in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after buying an additional 56 shares during the period. Fiduciary Financial Advisors purchased a new stake in United Therapeutics in the second quarter worth $30,000. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares during the period. Finally, Rakuten Securities Inc. lifted its holdings in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 46 shares during the period. 94.08% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
UTHR has been the topic of a number of research reports. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a report on Thursday, August 6th. Royal Bank Of Canada cut their target price on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. JPMorgan Chase & Co. raised their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a report on Thursday, July 23rd. Bank of America dropped their price target on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. Finally, Weiss Ratings upgraded shares of United Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday, August 13th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $646.00.
View Our Latest Stock Report on United Therapeutics
Insiders Place Their Bets
In related news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $541.39, for a total value of $5,143,205.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $21,933,333.07. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company's stock, valued at approximately $10,311,581.28. This trade represents a 34.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 424,075 shares of company stock valued at $227,336,485 over the last three months. Corporate insiders own 8.60% of the company's stock.
United Therapeutics Price Performance
Shares of UTHR opened at $527.91 on Friday. The firm has a market cap of $22.64 billion, a P/E ratio of 18.89, a price-to-earnings-growth ratio of 1.75 and a beta of 0.59. The company has a 50 day simple moving average of $530.89 and a two-hundred day simple moving average of $538.86. United Therapeutics Corporation has a 1 year low of $302.19 and a 1 year high of $609.35.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same period in the previous year, the business earned $6.41 earnings per share. The firm's revenue for the quarter was down 1.9% on a year-over-year basis. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current year.
United Therapeutics Company Profile
(
Free Report)
United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider United Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.
While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
